Additionally, the HER2-targeting antibody-drug conjugate (ADC) Enhertu<sup>®</sup> was recently approved for metastasized HER2-low cancers, confirming the benefits of HER2 treatment for patients with low HER2 levels. This evidence concerns the gene ERBB2 and cancer.